InsidersTradesSigma
NovaBay Pharmaceuticals, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the NovaBay Pharmaceuticals, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, NovaBay Pharmaceuticals, Inc. has logged 52 public disclosures. Market capitalisation: €51.9m. The latest transaction was reported on 15 April 2025 (Acquisition). Among the most active insiders: Kunin Audrey. All data is accessible without an account.
52
Insider Decl.
0
Thresholds
€845,575
32 ops.
Buy Volume
€140,913
8 ops.
Sell Volume
43Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 15 April 2025
Declarations52 total
25,033 shares@ US$0.619924.2% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007139:0
Ideal exit: 22 Nov 2025 (T+270)
14,645 shares@ US$0.5812.8% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007141:0
Ideal exit: 5 Dec 2025 (T+270)
14,000 shares@ US$0.6313.2% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007144:0
Ideal exit: 13 Dec 2025 (T+270)
2,597 shares@ US$0.6352.6% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007136:0
Ideal exit: 31 Oct 2025 (T+270)
31,703 shares@ US$0.6934.1% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007133:0
Ideal exit: 24 Oct 2025 (T+270)
917 shares@ US$0.580.8% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007148:0
Ideal exit: 28 Dec 2025 (T+270)
13,292 shares@ US$0.60912.3% of flowCommon Stock, par value $0.01 per shareSEC:0001398344-25-007146:0
Ideal exit: 21 Dec 2025 (T+270)
858 sharesCommon StockSEC:0001437749-23-014701:0
858 sharesCommon StockSEC:0001437749-23-014700:0
858 sharesCommon StockSEC:0001437749-23-014705:0
858 sharesCommon StockSEC:0001437749-23-014704:0
1 shares@ US$1.810.0% of flowCommon StockSEC:0001437749-22-028673:0
1 shares@ US$1.810.0% of flowCommon StockSEC:0001437749-22-028672:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028439:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028438:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028029:0
5,960 shares@ US$2.10492.8% of flowCommon StockSEC:0001437749-22-028031:0
291,368 shares@ US$0.158210.7% of flowCommon StockSEC:0001437749-22-022648:0
291,368 shares@ US$0.158210.7% of flowCommon StockSEC:0001437749-22-022646:0
10,000 shares@ US$0.152.8% of flowCommon StockSEC:0001437749-22-022651:0
Ideal exit: 11 Jun 2023 (T+270)
30,000 sharesCommon StockSEC:0001437749-22-013459:0
25 of 52 declarations
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. is a United States-based healthcare company listed on NYSE American, placing it within the broader NYSE/NASDAQ small-cap universe. The company is headquartered in Emeryville, California, and its business has historically centered on specialty ophthalmic, wound-care, and dermatology products built around its proprietary hypochlorous-acid platform. Over time, NovaBay built a niche commercial portfolio that included Avenova, NeutroPhase, PhaseOne, and the DERMAdoctor skincare brand. However, the company has undergone a major strategic reset in 2024–2025 following the divestiture of key operating assets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1389545/000182912625007607/novabay_ars.pdf?utm_source=openai)) From a historical perspective, NovaBay developed as a specialty healthcare and life-sciences company focused on anti-infective topical products for underserved markets rather than broad-based prescription pharmaceuticals. Avenova was its flagship eyecare product, positioned as an antimicrobial lid and lash spray; NeutroPhase and PhaseOne addressed wound-care use cases; and DERMAdoctor broadened the business into skincare and beauty. This mix gave NovaBay a hybrid profile spanning medical products and consumer-oriented health brands, but the company remained a small commercial platform with limited scale and a concentrated revenue base. ([novabay.com](https://novabay.com/pressreleases/novabay-pharmaceuticals-announces-new-partner-pharmacy-program/?utm_source=openai)) In competitive terms, NovaBay should be viewed as a repositioning micro-cap rather than a category leader. Management has emphasized clinically grounded products built on a proprietary, stable form of hypochlorous acid, but the company has faced competition from larger, better-capitalized players in ophthalmology, wound care, and dermatology. Recent SEC filings and company disclosures show that NovaBay completed the sale of Avenova in January 2025, and subsequently disclosed a financing transaction and broader efforts to preserve the public listing while pursuing a future strategic transaction. That makes the current equity story much more about corporate structure, liquidity, and optionality than about organic commercial expansion. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1389545/000182912625007607/novabay_ars.pdf?utm_source=openai)) Geographically, NovaBay is anchored in Emeryville, California, and its core commercial footprint has been the United States, although older product lines such as DERMAdoctor were distributed through international channels including North America, Europe, Asia, and Latin America. For investors, the key takeaway is that this is no longer a straightforward growth-story biotech; it is a restructuring situation with elevated execution risk, potential dilution, and dependence on governance and financing milestones. The most important recent developments are the asset sales, the leadership change tied to the 2025 financing agreement, and the company’s stated intention to support its listing while preparing for a potential strategic transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001389545/000182912625006520/novabay_ex99-1.htm?utm_source=openai))
